Combination tumor‐treating fields treatment for patients with metastatic non‐small cell lung cancer: A cost‐effectiveness analysis

Documents similaires

• Survival and safety analysis of COVID‐19 vaccine in Chinese patients with non‐small cell lung cancer
  par: Wei Xu, et autres
  Publié: (2024)
• Cost‐effectiveness analysis of osimertinib plus chemotherapy for patients with EGFR‐mutated advanced non‐small cell lung cancer
  par: Wentao Tian, et autres
  Publié: (2024)
• Referred molecular testing as a barrier to optimal treatment decision making in metastatic non‐small cell lung cancer: Experience at a tertiary academic institution in Canada
  par: Grace K. Grafham, et autres
  Publié: (2024)
• Optimum timing of lung resection surgery following SARS‐CoV‐2 infection for non‐small cell lung cancer
  par: Yanbo Yang, et autres
  Publié: (2024)
• Schizandrin A induces non‐small cell lung cancer apoptosis by suppressing the epidermal growth factor receptor activation
  par: Linhai Zhu, et autres
  Publié: (2024)